Treatment of unfavorable myelodysplastic syndrome with all-trans-retinoic acid and subcutaneous Ara C

Louis Letendre, Pierre Noel, William L. White, Ayalew Tefferi, Mark R. Litzow, Chin Yang Li, Georgene Schroeder

Research output: Contribution to journalArticle

6 Scopus citations

Abstract

Thirty patients with high-risk myelodysplastic syndrome, defined as>5% bone marrow blasts, were treated with a combination of oral all-trans-retinoic acid (45 mg/m2 daily) and subcutaneous AraC (10 mg/m2) on days 1-14 of each 28-35 day cycle repeated for 2-6 cycles. Complete remission lasting 9, 12, and 15 months was achieved in three patients. Partial and minor response did not translate into meaningful clinical improvement, like complete responders. Overall incidence of leukemia transformation and survival of this cohort of patients was no different from the expected outcome for a group of patients with similar characteristics. Copyright (C) 1999 Elsevier Science Ltd.

Original languageEnglish (US)
Pages (from-to)811-815
Number of pages5
JournalLeukemia Research
Volume23
Issue number9
DOIs
StatePublished - Sep 1 1999

Keywords

  • Chemotherapy
  • Leukemia
  • Myelodysplastic syndrome
  • Treatment

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Treatment of unfavorable myelodysplastic syndrome with all-trans-retinoic acid and subcutaneous Ara C'. Together they form a unique fingerprint.

  • Cite this